FGFR4 and neoplasm: Patients harboring FGFR4-R388 allele achieved a worse tumor response (9% vs. 25%) and a reduced median PFS (4.8 vs. 16.6 months) and OS (9.3vs 40 months) compared to patients homozygous for FGFR4-G388.